Anifrolumab (Saphnelo) listed in SK

May 1, 2024 – Lupus Canada is pleased to share that Lupus Awareness Month is kicking off with a Saphnelo listing in Saskatchewan effective May 1st, 2024.  With this listing, Saphnelo is now covered by 86% of Canadian public drug reimbursement plans.

For more information, you can visit the Saskatchewan Drug Plan website and enter ‘anifrolumab’ into the search bar or view the May Saskatchewan Formulary Bulletin.

Lupus Blog Articles:

The Lupus Canada Annual General Meeting 2026

Read

Disability Benefits in Canada | Pathway to Benefits

Read

Lupus Canada Impact Report 2025 | Advocacy, Awareness & Research Outcomes

Read